| | | |  | Volume 1, Number 4 (Winter 2012) |  | | | |  | Evaluation of Apolipoprotein A5 Polymorphism in Coronary- Heart Disease Patients |  |
 | | Author(s): Somayeh Haqparast *, Peyman Izadpanah, Abbas Abdollahi, Sohrab Najafipoor, Yaser Mansoori, Seyed Amin Koohpayeh , Mehdi Fasihi Radmandi | | | Study Type: Research | Subject: Medical Genetics | Receive: 2013/02/11 - Accept: 2013/09/14 - Publish: 2013/09/14 | | | Article abstract: | Background and Objectives: Apolipoprotein A5 (APOA5) gene is important in determining plasma triglyceride levels, a major cardiovascular disease risk factor. Mutation in this gene affected plasma triglyceride level. We looked for possible associations of the APOA5 gene polymorphism S19W with coronary heart disease (CHD) in a sample of Iranian population.
Materials and Methods: A total of 73 CHD patients and 55 controls were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) for this single nucleotide polymorphism. Serum lipids and Fast Blood Sugar concentrations were measured in all subjects with enzymatic method.
Results: Allele frequencies observed in our population were 0.041 for the W allele and 0.959 for the S allele which are similar to other populations (p>0.05). There is no evidence that APOA5 S19W, is a risk factor of CHD in our sample (p>0.05). In addition, we observed no association between the APOA5 W allele and elevated plasma TG levels (p>0.05) in the CHD group. This result was also present in the control group (p>0.05).
Conclusion: The APO A5 gene polymorphism in S19W gene has no association with the high susceptibility to CHD. | | | Keywords: Keywords: Apolipoprotein A5, Coronary heart disease, Polymorphism, PCR-RFLP, | | | Full text [PDF 1124 kb] | | | | | | How to cite this article | Download citation data for: BibTeX | EndNote | Medlars | ProCite | Reference Manager | RefWorks |
Send citation data to: CiteULike | RefWorks | | | | | | | | Add your comments about this article | | | | | | | | | | |
